Abstract YO30
Case summary
A 53-year-old man presented with an 11-month history of a painless neck mass. On examination, he had a 10 x 5 cm mass at the left carotid triangle, and a fungating mass at the left tonsillar fossa, which on CT scan was 3.2 x 2.2 cm and invading into the parapharyngeal space.
Biopsy revealed an undifferentiated malignancy. Immunohistochemistry was negative for CK, LCA, EMA, synaptophysin, chromogranin and 34beta-E12, positive for vimentin and focally positive for S-100, favoring malignant melanoma. However, both HMB-45 and melan-A were negative, leading to a classification of undifferentiated sarcoma.
Chest and abdominal CT scan were negative for distant metastases. The tumor was deemed unresectable due to its close attachment to the great vessels, hence a sequential chemoradiation approach was pursued. He underwent six cycles of doxorubicin (60 mg/m2), resulting in 80% tumor regression. Unfortunately, he was lost to follow-up and was unable to undergo radiotherapy. He returned eight months later with re-enlargement of the neck mass to 6 x 5 cm. He remained free of distant metastases, and underwent two cycles of dacarbazine (250 mg/m2, day 1-5), which did not confer any response.
The indolent behavior of the tumor prompted pathological re-evaluation. Further staining showed diffuse positivity for CD21 and negative for CD1A and CD34, consistent with follicular dendritic cell sarcoma. The patient underwent three cycles of gemcitabine (1000 mg/m2, day 1 and 8) plus docetaxel (75 mg/m2, day 1), resulting in 50% tumor regression. This allowed dissection of level IB – V lymph nodes, which found disease in 10/23 nodes. He subsequently underwent adjuvant radiotherapy for the neck and primary radiotherapy for the tonsillar mass, with weekly gemcitabine (400 mg/m2) as a radiosensitizer. Evaluation three months post-treatment did not show any sign of disease progression.
Follicular dendritic cell sarcoma is very rare, accounting for <0.4% of soft tissue sarcomas. Only 60 cases of tonsillar occurrence have been reported in literature. Tonsillectomy is sufficient in most cases. For our patient, a trimodality approach done due to the presence of high risk features (R2 resection, LN involvement, tumor recurrence) provided good disease control.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract